DIPRODRUG Research Group

Dietary Proteins and Drug Development for Type 2 Diabetes and Obesity

This project aims to develop new antidiabetic and anti-obesity drugs for the fight against type 2 diabetes, postprandial lipemia and its complications. Drugs will be developed from new plant-, fungus-, and bacteria-derived substances. Part of the project is a new drug based on steviol. Its high efficiacy in lowering blood sugar and reducing body weight is sufficiently described in the literature. This drug will be used for clinical trials within the project. Two new further drug candidates based on plant and fungus substances will be developed. Furthermore, nutritional therapies bases on new milk bacteria and derivatives will be applied in clinical trials to determine their beneficial effects on postprandial lipemia, blood sugar and obesity. The project is scheduled for a period of 4 years. The consortium consists of 7 academic centers and 3 medium-sized enterprises.

If you are interested in this project and if you would like to learn more about the details, do not hesitate to contact us by mail at diprodrug(at)soc-bdr.org.